Polyplus - Sartorius
Polyplus-transfection® is a French biotechnology company specializing in nucleic acid delivery solutions for research, bioproduction, and advanced therapies. Now part of Sartorius’s Bioprocess Solutions division since 2023, the company is a global leader in transfection technologies that enable the development and manufacturing of cell and gene therapies.
Its core expertise lies in high-efficiency chemical transfection reagents for introducing DNA, RNA, or siRNA into eukaryotic cells. The flagship PEIpro® line has become the industry standard for viral vector production, offered in research to GMP grades.
For in vitro research, Polyplus provides reagents like jetPRIME®, jetOPTIMUS®, INTERFERin®, and jetMESSENGER®, ensuring superior transfection efficiency and low cytotoxicity across cell types. Their in vivo-jetPEI® supports preclinical delivery.
Expanding beyond reagents, Polyplus now offers plasmid and protein manufacturing services, delivering end-to-end solutions for the gene therapy workflow. Headquartered in Strasbourg, the company operates under ISO 9001 certification, ensuring uncompromising quality.
